LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL RESULTS INVOLVING ADVANCED OVARIAN CANCER PATIENTS TREATED WITH VIGIL® IN FRONTLINE MAINTENANCE

Sunday, July 26, 2020